Literature DB >> 23175673

Estrogen receptor-mediated regulation of microRNA inhibits proliferation of vascular smooth muscle cells.

Jin Zhao1, Gregory A Imbrie, Wendy E Baur, Lakshmanan K Iyer, Mark J Aronovitz, Tanya B Kershaw, Greta M Haselmann, Qing Lu, Richard H Karas.   

Abstract

OBJECTIVE: Estradiol (E2) regulates gene transcription by activating estrogen receptor-α and estrogen receptor-β. Many of the genes regulated by E2 via estrogen receptors are repressed, yet the molecular mechanisms that mediate E2-induced gene repression are currently unknown. We hypothesized that E2, acting through estrogen receptors, regulates expression of microRNAs (miRs) leading to repression of expression of specific target genes. METHODS AND
RESULTS: Here, we report that E2 significantly upregulates the expression of 26 miRs and downregulates the expression of 6 miRs in mouse aorta. E2-mediated upregulation of one of these miRs, miR-203, was chosen for further study. In cultured vascular smooth muscle cells (VSMC), E2-mediated upregulation of miR-203 is mediated by estrogen receptor-α (but not estrogen receptor-β) via transcriptional upregulation of the primary miR. We demonstrate that the transcription factors Zeb-1 and AP-1 play critical roles in mediating E2-induced upregulation of miR-203 transcription. We show further that miR-203 mediates E2-induced repression of Abl1, and p63 protein abundance in VSMC. Finally, knocking-down miR-203 abolishes E2-mediated inhibition of VSMC proliferation, and overexpression of miR-203 inhibits cultured VSMC proliferation, but not vascular endothelial cell proliferation.
CONCLUSIONS: Our findings demonstrate that E2 regulates expression of miRs in the vasculature and support the estrogen receptors-dependent induction of miRs as a mechanism for E2-mediated gene repression. Furthermore, our findings demonstrate that miR-203 contributes to E2-induced inhibition of VSMC proliferation and highlight the potential of miR-203 as a therapeutic agent in the treatment of proliferative cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23175673      PMCID: PMC3780598          DOI: 10.1161/ATVBAHA.112.300200

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  43 in total

Review 1.  Combinatorial control of gene expression by nuclear receptors and coregulators.

Authors:  Neil J McKenna; Bert W O'Malley
Journal:  Cell       Date:  2002-02-22       Impact factor: 41.582

2.  Estrogen induces distinct patterns of microRNA expression within the mouse uterus.

Authors:  Warren B Nothnick; Caitlin Healy
Journal:  Reprod Sci       Date:  2010-08-18       Impact factor: 3.060

Review 3.  Estrogen receptor pathways to AP-1.

Authors:  P J Kushner; D A Agard; G L Greene; T S Scanlan; A K Shiau; R M Uht; P Webb
Journal:  J Steroid Biochem Mol Biol       Date:  2000-11-30       Impact factor: 4.292

4.  Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells.

Authors:  Pedro de Souza Rocha Simonini; Achim Breiling; Nibedita Gupta; Mahdi Malekpour; Mahmoud Youns; Ramesh Omranipour; Fatemeh Malekpour; Stefano Volinia; Carlo M Croce; Hossein Najmabadi; Sven Diederichs; Ozgür Sahin; Doris Mayer; Frank Lyko; Jörg D Hoheisel; Yasser Riazalhosseini
Journal:  Cancer Res       Date:  2010-10-26       Impact factor: 12.701

5.  Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice.

Authors:  R H Karas; J B Hodgin; M Kwoun; J H Krege; M Aronovitz; W Mackey; J A Gustafsson; K S Korach; O Smithies; M E Mendelsohn
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

6.  Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury.

Authors:  Gary Pare; Andrée Krust; Richard H Karas; Sonia Dupont; Mark Aronovitz; Pierre Chambon; Michael E Mendelsohn
Journal:  Circ Res       Date:  2002-05-31       Impact factor: 17.367

7.  The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs.

Authors:  Ulrich Wellner; Jörg Schubert; Ulrike C Burk; Otto Schmalhofer; Feng Zhu; Annika Sonntag; Bettina Waldvogel; Corinne Vannier; Douglas Darling; Axel zur Hausen; Valerie G Brunton; Jennifer Morton; Owen Sansom; Julia Schüler; Marc P Stemmler; Christoph Herzberger; Ulrich Hopt; Tobias Keck; Simone Brabletz; Thomas Brabletz
Journal:  Nat Cell Biol       Date:  2009-11-22       Impact factor: 28.824

8.  Protein kinase C-dependent upregulation of miR-203 induces the differentiation of human keratinocytes.

Authors:  Enikö Sonkoly; Tianling Wei; Elizabeth Pavez Loriè; Hiroyuki Suzuki; Mitsuyasu Kato; Hans Törmä; Mona Ståhle; Andor Pivarcsi
Journal:  J Invest Dermatol       Date:  2010-01       Impact factor: 8.551

9.  MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines.

Authors:  Giuditta Viticchiè; Anna Maria Lena; Alessia Latina; Amanda Formosa; Lea H Gregersen; Anders H Lund; Sergio Bernardini; Alessandro Mauriello; Roberto Miano; Luigi G Spagnoli; Richard A Knight; Eleonora Candi; Gerry Melino
Journal:  Cell Cycle       Date:  2011-04-01       Impact factor: 4.534

10.  MicroRNA-203 inhibits cell proliferation by repressing ΔNp63 expression in human esophageal squamous cell carcinoma.

Authors:  Yang Yuan; Zhi-Yong Zeng; Xiao-Hong Liu; De-Jun Gong; Jing Tao; He-Zhong Cheng; Sheng-Dong Huang
Journal:  BMC Cancer       Date:  2011-02-07       Impact factor: 4.430

View more
  20 in total

Review 1.  An overview of potential molecular mechanisms involved in VSMC phenotypic modulation.

Authors:  Ming-Jie Zhang; Yi Zhou; Lei Chen; Yan-Qin Wang; Xu Wang; Yan Pi; Chang-Yue Gao; Jing-Cheng Li; Li-Li Zhang
Journal:  Histochem Cell Biol       Date:  2015-12-26       Impact factor: 4.304

2.  Arterial smooth muscle.

Authors:  Valerie Z Wall; Karin E Bornfeldt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-10       Impact factor: 8.311

3.  Oestrogen signalling in white adipose progenitor cells inhibits differentiation into brown adipose and smooth muscle cells.

Authors:  Kfir Lapid; Ajin Lim; Deborah J Clegg; Daniel Zeve; Jonathan M Graff
Journal:  Nat Commun       Date:  2014-10-21       Impact factor: 14.919

4.  Regulation of Vascular Smooth Muscle Cell Dysfunction Under Diabetic Conditions by miR-504.

Authors:  Marpadga A Reddy; Sadhan Das; Chen Zhuo; Wen Jin; Mei Wang; Linda Lanting; Rama Natarajan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-03-03       Impact factor: 8.311

5.  Deletion of yes-associated protein (YAP) specifically in cardiac and vascular smooth muscle cells reveals a crucial role for YAP in mouse cardiovascular development.

Authors:  Yong Wang; Guoqing Hu; Fang Liu; Xiaobo Wang; Mingfu Wu; John J Schwarz; Jiliang Zhou
Journal:  Circ Res       Date:  2014-01-29       Impact factor: 17.367

6.  miR-222 contributes to sex-dimorphic cardiac eNOS expression via ets-1.

Authors:  Alicia M Evangelista; Anne M Deschamps; Delong Liu; Nalini Raghavachari; Elizabeth Murphy
Journal:  Physiol Genomics       Date:  2013-04-30       Impact factor: 3.107

Review 7.  miRNAs regulated by estrogens, tamoxifen, and endocrine disruptors and their downstream gene targets.

Authors:  Carolyn M Klinge
Journal:  Mol Cell Endocrinol       Date:  2015-02-03       Impact factor: 4.102

8.  Estrogen regulation of protein expression and signaling pathways in the heart.

Authors:  Elizabeth Murphy; Charles Steenbergen
Journal:  Biol Sex Differ       Date:  2014-03-10       Impact factor: 5.027

9.  Atherosclerosis and Vascular Biologic Responses to Estrogens: Histologic, Immunohistochemical, Biochemical, and Molecular Methods.

Authors:  Thomas C Register; Susan E Appt; Thomas B Clarkson
Journal:  Methods Mol Biol       Date:  2016

10.  Estrogen regulates the tumour suppressor MiRNA-30c and its target gene, MTA-1, in endometrial cancer.

Authors:  Xiangyi Kong; Xiaofeng Xu; Yuhua Yan; Feifei Guo; Jian Li; Yali Hu; Huaijun Zhou; Qingying Xun
Journal:  PLoS One       Date:  2014-03-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.